Please ensure Javascript is enabled for purposes of website accessibility

Why Galapagos Stock Is Crashing Today

By Keith Speights – Aug 19, 2020 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA dealt the biotech and its big partner a huge setback.

What happened

Shares of Galapagos (GLPG -0.21%) were crashing 24.6% lower as of 11:14 a.m. EDT on Wednesday. The big drop came after the biotech's partner, Gilead Sciences (GILD 0.44%), announced that it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its regulatory filing for approval of filgotinib in treating rheumatoid arthritis. Gilead teamed up with Galapagos on development of the investigational drug in 2015.

So what

The FDA requested data from the MANTA and MANTA-RAy clinical studies evaluating filgotinib in other indications before completing its review of the regulatory filing for the drug in treating rheumatoid arthritis. Data from these studies won't be available until the first half of 2021.

Man with thumb pointing down

Image source: Getty Images.

This is bad news all by itself for both Galapagos and Gilead. It means that any potential FDA approval and commercial launch of filgotinib could be pushed back well over a year.

But there's even worse news: Gilead stated that the FDA "expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose." This could possibly jeopardize the chances of approval for filgotinib in rheumatoid arthritis or any other targeted indication.

Investors were counting on filgotinib becoming a blockbuster for Gilead and generating billions of dollars over the long run for Galapagos. The FDA's thumbs-down creates considerable uncertainty for Galapagos' prospects. 

Now what

Gilead's chief medical officer, Merdad Parsey, stated that the company "will evaluate the points raised in the CRL for discussion with the FDA." However, Gilead also noted that filgotinib recently received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Merdad said that Gilead "continue[s] to believe in the benefit/risk profile of filgotinib" in treating rheumatoid arthritis.

Until the dust settles, it's likely that Galapagos' share price will remain highly volatile. Investors are probably best steering clear of the biotech stock in the meantime.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Galapagos Stock Quote
$42.55 (-0.21%) $0.09
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.96 (0.44%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.